This trial included 237 patients with HER2 positive and HR positive advanced breast cancer who had previously been treated with at least two antiHER2 targeted therapies of abemaciclib, trastuzumab and fulvestrant, abemaciclib with trastuzumab, or chemotherapy plus trastuzumab. Here, ERBB2 is linked to breast carcinoma.